9 / 13
Page 23
Volume 3
Journal of Pharmacology and Medicinal Chemistry
Nanomedicine 2019
Biotechnology 2019
May 20-21, 2019
May 20-21, 2019 London, UK
4
th
World Biotechnology CONGRESS
Nanomedicine and Nanotechnology
4
th
International Conference on
&
Highly stable
E. coli
–expressed humanized anti-EGFR scFv
Kamal Veisi
Shahid Beheshti University of Medical Sciences, Iran
I
n the current work, we show how to design an intrinsically stable single chain antibody (scFv) that can be easily produced in
bacterial expression systems as a soluble protein. Summarily, CDR loops are grafted on intrinsically stable framework regions
derived from VH3 and VL3 human germline sequences. Human VH3 and VL3 candidates should carry CDR loops with desired
canonical classes and contain special residues in their hydrophobic cores. Recombinant variable fragments resultant from CDR
grafting are subjected to 3D modeling, mutated (if necessary), and superposed to parental variable domains. Recombinant type
3 variable domains with the least RMSD (Root-Mean-Square Deviation) values are chosen to constitute scFv moieties. The scFv
designed using this method was shown to be soluble when expressed in bacterial cells and able to recognize EGFR-overexpressing
cancer cells.
Biography
Kamal Veisi has completed his PhD degree in medical biotechnology. He is an Assistant professor of Shahid Beheshti University of
Medical Sciences and Kermanshah University of Medical Sciences, his research interest is antibody engineering.
k.veissie@gmail.comJ Pharmacol Med Cheml, Volume 3